PP-SM1: GLP-1 Receptor Agonist Research

PP-SM1 is a glucagon-like peptide-1 (GLP-1) receptor agonist studied in relation to glucose regulation and body weight endpoints. Published research describes it as mimicking the action of the GLP-1 incretin hormone, with documented effects on satiety signalling, appetite and the rate of gastric emptying.

The summary below describes findings reported in the published literature. PP-SM1 is supplied for laboratory research use only and is not approved for human or veterinary use. No conclusions can be drawn regarding safety or effects in humans.

Structurally, PP-SM1 comprises the GLP-1 backbone with γ-glutamate linkers connected to a C18 stearic diacid spacer. Human serum albumin binds at the carboxylic acid group at the end of the C18 chain, which is the basis of its extended half-life.

PP-SM1's Mechanism of Action

As a GLP-1 receptor agonist, PP-SM1 has documented activity at the brain, stomach, pancreas and small intestine. Reported effects by tissue:

• Small intestine: PP-SM1 amplifies the incretin effect — the release of hormones in response to nutrient intake. Studies have measured increased release of incretin hormones such as GLP-1 following nutrient consumption.

• Nutrient absorption: The principal documented action relates to hormone signalling and glycemic control rather than direct absorption. Any effect on nutrient absorption in the small intestine is described in the literature as indirect, via the incretin effect.

• Stomach: PP-SM1 slows the passage of food from stomach to small intestine, a phenomenon known as delayed gastric emptying. Studies have associated this with prolonged satiety signalling and reduced food intake.

• Appetite signalling: The rate of gastric emptying is one input to appetite regulation, and delayed emptying has been shown to alter those signals.

• Insulin secretion: In response to elevated blood glucose, PP-SM1 prompts pancreatic beta-cells to increase insulin production.

• Glucagon suppression: PP-SM1 reduces glucagon secretion from pancreatic alpha-cells. Because glucagon acts to raise blood glucose, this contributes to the observed effect on glucose levels.

• Central appetite regulation: Studies report activity at appetite centres in the brain, with measured reductions in hunger signalling and caloric intake, and increased satiety signalling.

Research: Reported Clinical Findings

Published research has measured the effect of PP-SM1 on body weight endpoints and cardiometabolic markers, and has examined associations with diabetes risk and physical function scores.

Body weight endpoints

In the STEP studies, participants recorded a mean reduction in body weight of 6% at 12 weeks and 12% at 28 weeks.

A real-world study reported a mean reduction of 10% over six months. A separate study reported mean reductions of 13.6% and 12.8% at two exposure levels; study protocols varied, see the cited publications. In a longitudinal study, participants receiving PP-SM1 recorded greater reductions in body weight than those receiving placebo.

Cardiometabolic markers

A real-world investigation reported decreases in total cholesterol and triglycerides among participants receiving PP-SM1. A separate trial reported changes in physical functioning scores.

Adverse events reported in trials

In one trial, most reported adverse events were classified as mild to moderate and did not lead to discontinuation. Separate research reported no elevated risk of thyroid problems among participants receiving PP-SM1 compared with placebo. These are findings from specific published trials and are not a safety characterisation of the research material supplied here, for which no safety profile has been established.

Areas of Study

• Body weight research: A principal research application examines change in body weight in trial participants with obesity, notably through the STEP programme.

• Type 2 diabetes research: PP-SM1 is investigated in clinical studies measuring blood glucose endpoints and cardiovascular risk markers associated with the condition.

• Mode of action: Work continues on its activity as a GLP-1 receptor agonist and the associated satiety and hunger signalling pathways.

• Exposure-range studies: Clinical research investigates a range of PP-SM1 exposure levels to characterise exposure-response across weight and glycemic endpoints.

• Combination studies: Research evaluates PP-SM1 alongside other pharmacological agents against weight and glucose endpoints.

Emerging Research Directions

Reported open questions in the PP-SM1 literature include:

• Response predictors: Identifying characteristics that predict how a trial participant responds.

• Long-term safety profile: Characterising safety over extended administration periods.

• Duration: Establishing appropriate intervention duration in study protocols.

• Maintenance schedules: Determining the lowest maintenance exposure levels with measurable activity in trials.

• Individual variation: Understanding sources of variation in measured response across study populations.

Research use statement. PP-SM1 supplied by Power Peptides is intended for laboratory research use only and is not approved by the U.S. Food and Drug Administration for human or veterinary use. It is not a drug, food or cosmetic, and must not be used in humans or animals.

References

1. Tilinca, M. C., Tiuca, R. A., Niculas, C., Varga, A., & Tilea, I. (2021). Future perspectives in diabesity treatment: PP-SM1, a glucagon‑like peptide 1 receptor agonist. Experimental and Therapeutic Medicine, 22(4), 1-11.

2. Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023). PP-SM1 for the treatment of overweight and obesity: a review. Diabetes, Obesity and Metabolism, 25(1), 18-35.

3. Papakonstantinou, I., Tsioufis, K., & Katsi, V. (2024). Spotlight on the Mechanism of Action of PP-SM1. Current Issues in Molecular Biology, 46(12), 14514-14541.

4. Williams, D. M., & Evans, M. (2020). PP-SM1: charting new horizons in GLP-1 analogue outcome studies. Diabetes Therapy, 11(10), 2221-2235.

5. Fallows, E., Ells, L., & Anand, V. (2023). PP-SM1 and the future of obesity care in the UK. The Lancet, 401(10394), 2093-2096.